Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 7/20 | 0.47 |
| ▸ | CYP2A13 | Q16696 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | LGMN | Q99538 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22662669 | 0.83 | KEAP1 (0.47) | GAAMAPTSMN1; SMN2CNR2ALDH1A1 | |
| SCHEMBL5092052 | 0.81 | KEAP1 (0.50) | SMN1; SMN2CNR2ALDH1A1LMNAKDM4E | |
| SCHEMBL29931924 | 0.81 | KEAP1 (0.50) | SMN1; SMN2CNR2ALDH1A1LMNAKDM4E | |
| SCHEMBL4435301 | 0.80 | LGMN (0.50) | GAAMAPTSMN1; SMN2ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL29978819 | 0.80 | KEAP1 (0.48) | GAAMAPTSMN1; SMN2CNR2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL23043631 | 0.80 | KEAP1 (0.48) | GAAMAPTSMN1; SMN2CNR2ALDH1A1 | |
| SCHEMBL613154 | 0.79 | ADRB1 (0.55) | ALDH1A1 | |
| SCHEMBL13724280 | 0.79 | AR (0.42) | GAAMAPTSMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL16943272 | 0.79 | ALDH1A1 (0.47) | SMN1; SMN2CNR2CYP2A13ALDH1A1LMNA | |
| SCHEMBL3723928 | 0.79 | ALDH1A1 (0.54) | GAAMAPTCNR2CYP2A13ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230104936-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| EP-4076423-A1 | TRPML MODULATORS | Casma Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115087440-A | TRPML modulators | 卡斯玛治疗公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2021127337-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2010125103-A1 | DIKETOPIPERAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230104936-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | GAA 2832/4885MAPT 1167/4885SMN1; SMN2 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.